Physician profile
Scott J Low
NPI 1689614091
$1,177.43
in general payments reported to CMS, 2019-2025
17 companies · $58.04 in 2025
The $58.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $196 · 2021: $14.82 · 2022: $23.42 · 2024: $42.08 · 2025: $58.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $172.08 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.12 | 2019 | |
| Glaxosmithkline, LLC. | $100.93 | 2019 | |
| Abbvie INC. | $100.12 | 2024-2025 | |
| Allergan, INC. | $85.40 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.13 | 2019 | |
| Lilly USA, LLC | $73.23 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $69.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $60.07 | 2019-2020 | |
| Sanofi Pasteur INC. | $48.13 | 2019 | |
| Astellas Pharma US INC | $45.98 | 2019-2020 | |
| Novo Nordisk INC | $45.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $32.72 | 2019 | |
| Merck Sharp & Dohme LLC | $26.94 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $23.13 | 2020 | |
| Amgen INC. | $17.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Low listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.